Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria

• DOI: 10.1016/j.jconrel.2022.05.044
• Publication Date: 2022-06-10T01:20:42Z
• Authors: Yiqing Zou; Xiaonan Chen; Yingying Sun; Pengyu Li; Mao Xu; Pengchao Fang; Shuqi Zhang; Gang Yuan; Xin Deng; Haiyan Hu
• Keywords: Linoleic Acid; 0303 health sciences; 03 medical and health sciences; Helicobacter pylori; Biofilms; Humans; Nanoparticles; Urease; Anti-Bacterial Agents; Helicobacter Infections

Biofilms and intracellular survival tremendously help Helicobacter pylori (H. pylori) escape from antibacterial agents attacking, therefore issuing extreme challenges to clinical therapies. Herein, we constructed fucoidan (FU)-coated nanoparticles (FU/ML-LA/EB NPs) via simple self-assembly of biguanide derivative (metformin-linoleic acid, ML) and linoleic acid (LA), encapsulating urease inhibitor ebselen (EB) instead of antibiotics to take antibacterial effect. Negatively charged FU/ML-LA/EB NPs easily penetrated through the gastric mucus layer to arrive at infection sites, then eradicated extracellular polymeric substances (EPS) to destroy H. pylori biofilms structure. After strengthening bacterial membrane permeability, the nanoparticles could enter H. pylori and kill bacteria by inhibiting the activity of urease. FU/ML-LA/EB NPs also entered H. pylori-infected host cells through receptor-mediated internalization, in which they activated AMPK to recover lysosomal acidification for killing intracellular H. pylori. Additionally, FU/ML-LA/EB NPs alleviated oxidative stress, hence reducing gastric mucosal damage and cutting off the pathways of carcinogenesis. Notably, H. pylori burden after FU/ML-LA/EB NPs treatment was reduced to a great extent in vivo, which was significantly lower than that after treatment with clinical therapy. Antibiotics-free FU/ML-LA/EB NPs improving bacterial eradication and alleviating oxidation stress made it a powerful approach against H. pylori.